ChemicalBook > Product Catalog >API >Antineoplastic agents >Alkylating antineoplastic >Estramustine sodium phosphate

Estramustine sodium phosphate

Estramustine sodium phosphate Suppliers list
Company Name: Xiamen AmoyChem Co., Ltd
Tel: +86-592-6051114 +8618959220845
Email: sales@amoychem.com
Products Intro: Product Name:Estramustinephosphatesodium
CAS:52205-73-9
Company Name: Hubei xin bonus chemical co. LTD
Tel: 86-13657291602
Email: linda@hubeijusheng.com
Products Intro: Product Name:(17-beta)-Estra-1,3,5(10)-triene-3,17-diol 3-(bis(2-chloroethyl)carbamate) 17-(dihydrogenphosphate) disodium salt
CAS:52205-73-9
Purity:0.99 Package:5KG;1KG
Company Name: CONIER CHEM AND PHARMA LIMITED
Tel: +8618523575427
Email: sales@conier.com
Products Intro: Product Name:estramustine phosphate sodium
CAS:52205-73-9
Purity:99% Package:1kg
Company Name: career henan chemical co
Tel: +86-0371-86658258 15093356674;
Email: factory@coreychem.com
Products Intro: Product Name:Estramustine sodium phosphate
CAS:52205-73-9
Purity:98% Package:1KG;3USD
Company Name: SIMAGCHEM CORP
Tel: +86-13806087780
Email: sale@simagchem.com
Products Intro: Product Name:Estramustinephosphatesodium
CAS:52205-73-9
Purity:0.99 Package:1kg,5kg,25kgs,200kgs;bulk

Estramustine sodium phosphate manufacturers

Estramustine sodium phosphate Basic information
Product Name:Estramustine sodium phosphate
Synonyms:ESTRAMUSTINE PHOSPHATE SODIUM;-(dihydrogenphosphate),disodiumsalt;iumphosphate;Estra-1,3,5(10)-triene-3,17-diol (17beta)-, 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt;Estra-1,3,5(10)-triene-3,17-diol (17β)-, 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate), disodium salt;Estracyt;Estramustine phosphate disodium salt;NSC 89199
CAS:52205-73-9
MF:C23H33Cl2NNaO6P
MW:544.38
EINECS:257-735-7
Product Categories:Active Pharmaceutical Ingredients;Intermediates;Other APIs
Mol File:52205-73-9.mol
Estramustine sodium phosphate Structure
Estramustine sodium phosphate Chemical Properties
storage temp. Inert atmosphere,2-8°C
solubility H2O: soluble50mg/mL
form A crystalline solid
color White to off-white
Stability:Hygroscopic, Unstable in Solution
CAS DataBase Reference52205-73-9(CAS DataBase Reference)
Safety Information
Hazard Codes Xi
Risk Statements 37
Safety Statements 26
WGK Germany 3
RTECS KG7350000
HS Code 29242990
MSDS Information
Estramustine sodium phosphate Usage And Synthesis
DescriptionEstramustine phosphate is a derivative of estradiol (Item Nos. 20776 | 10006315) that contains a nor-nitrogen mustard group. Estramustine phosphate destabilizes microtubules by binding to microtubule-associated proteins (MAPs) with Kd values of 10 and 15 μM for MAP-1 and MAP-2, respectively. Estramustine induces cell cycle arrest in mitosis at the metaphase stage in DU145 and PC3 prostate cancer cells and induces apoptosis in U87MG human malignant glioma cells. The metabolites of estramustine phosphate have anti-androgenic effects. Formulations containing estramustine phosphate are used in the palliative treatment of prostate cancer.
UsesEstramustine phosphate sodium USP (Emcyt) is used to treat Prostatic carcinoma.
UsesAntineoplastic.
UsesEstramustine sodium phosphate is binds estradiol receptors irreversibly.
DefinitionChEBI: An organic sodium salt which is the disodium salt of estramustine phosphate.
Brand nameEmcyt (Pharmacia & Upjohn).
General DescriptionEstramustine as the phosphate is available in 140-mg capsulesfor the treatment of prostate cancer. Although originallydesigned as an alkylating agent, it has been shown tobe devoid of alkylating activity and functions as an inhibitorof microtubule function by binding to microtubule associate proteins (MAPs) and also binds to tubulin at a site that isdistinct from that of the vinca alkaloids but thought to partiallyoverlap with that of pacilataxel.The major mechanismby which cells become resistant to the agent involvesincreased efflux, although this is not mediated by Pgp as isthe case with other microtubule inhibitors such as the taxanesand vinca alkaloids. Therefore, the agent does not showcross-resistance with these agents. As an inhibitor of microtubules,it is cell cycle specific acting in the M phase. Theagent is well absorbed upon oral administration with hydrolysisof the water solubilizing phosphate beginning to occurin the GI tract. Metabolism involves the formation of theactive estromustine, which arises from oxidation of the C17alcohol to give the ketone. Additional inactive metabolitesresult from carbamate hydrolysis to give estradiol and estrone.The parent and metabolites are primarily eliminatedin the feces with a terminal elimination half-life of 20 hours.The adverse effects of the agent are nausea and vomiting,which is generally mild but the severity may increase uponprolonged administration. Gynecomastia also commonlyoccurs, and diarrhea may also be seen. Less commonly seeneffects include myelosuppression, skin rash, and cardiovascularabnormalities including CHF.
Estramustine sodium phosphate Preparation Products And Raw materials
Tag:Estramustine sodium phosphate(52205-73-9) Related Product Information
Digold trioxide Dexamethasone 21-phosphate disodium salt sodium hexametaphosphate Pentasodium triphosphate hexhydrate Estramustine Phosphoric acid, isooctyl ester 4-cyclohexyl-phenol carbamate MPMC PHOSPHORIC ACID MONO-N-DODECYL ESTER SODIUM SALT 2-Chloroethyl carbamate (2-ETHYLHEXYL) PHOSPHATE DIETHYL-CARBAMIC ACID PHENYL ESTER estra-1,3,5(10)-triene-3,17beta-diol 3-[bis(2-chloroethyl)carbamate] 17-(dihydrogen phosphate) Estramustine sodium phosphate